- Home
- UTL vs RLAY Comparison
UTL vs RLAY Comparison
Compare UTL & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | RLAY |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 1.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | UTL | RLAY |
|---|---|---|
| Price | $49.90 | $7.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $55.00 | $16.00 |
| AVG Volume (30 Days) | 122.2K | ★ 2.3M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $502,000,000.00 | $8,355,000.00 |
| Revenue This Year | $5.98 | $20.47 |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | $17.51 | ★ N/A |
| Revenue Growth | ★ 1.03 | N/A |
| 52 Week Low | $44.61 | $1.78 |
| 52 Week High | $60.48 | $8.36 |
Technical Indicators
Market Signals| Indicator | UTL | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 61.66 |
| Support Level | $49.21 | $7.23 |
| Resistance Level | $51.00 | $8.36 |
| Average True Range (ATR) | 0.97 | 0.51 |
| MACD | 0.17 | 0.06 |
| Stochastic Oscillator | 79.34 | 73.71 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).